Client-centric solutions with multichannel integration
Actionable insights on pricing and reimbursement, market access and health economic issues across the product lifecycle.
Our strategic guidance draws on unique resources, tools and knowledge, tailored to meet your needs.
InterPhase P&MA is a key partner to global pharmaceutical, biotechnology and medical device companies. We solve complex problems through bespoke approaches targeting the most pertinent issues.
As part of the KnowledgePoint360 Group, we have access to over 25 years of company experience across a countless of brands, therapy areas, and geographies.
Our offices are located in the US (East and West coast), UK and Germany, allowing us to deliver global projects underpinned by local knowledge.
Leadership Team
Richard Lawrence
President of InterPhase
Richard has extensive experience in product development and commercialisation strategies. He held senior roles in 3 major blue chip Pharma companies over an 18 year period, prior to 8 years in communications and consultancy.
Lee Forster
VP and Global Head
of Pricing & Market Access
Lee brings a wealth of knowledge, having had extensive experience working with global pharmaceutical companies, biotechs, device manufacturers, regulatory bodies and national governments across numerous markets, methodologies and therapy areas.
We provide concise,
action-oriented outputs and
recommendations, underpinned
by specialist expertise.
Consulting Expertise
Market Access - maximising product availability by demonstrating value to payers
Pricing and Reimbursement - achieving optimal pricing and overcomingm restrictions to reimbursement
Health Economics and Outcomes Research - providing quantitative evidence to support product value propositions
Global Reach
Therapy Area
Selected examples of how InterPhase P&MA provides insights and value to our clients
Product value assessment
We have evaluated early stage products, recommending strategies to maximise long-term value
Evidence planning
We have evaluated evidence expectations and product price potential in multiple myeloma
Segmentation
We have utilised segmentation approaches to optimise value messaging at launch
Global pricing strategy
We have developed global pricing strategies, underpinned by market-specific price sensitivity analyses
LOE strategy
We have evaluated payer partnership initiatives to defend market share following LOE
Our bespoke solutions draw on unique resources, tools & knowledge
Our Network gives us instant access to the most relevant KOLs and Payers
We draw on proprietary search and validation tools to target top KOLs
Our extensive managed network includes key Payers across geographies
Our Tools provide innovative and customisable approaches to complex client issues
InFORM: Payer segmentation, allocation and engagement
PROSPECT: multi-attribute decision support
EXTRA: bias reduction in small samples
Our Intelligence is built onunrivalled industry experience and unique in-house resources
Direct access to KnowledgePoint360's data assets and therapy area knowledge from individuals with first-hand experience in the field
A dedicated Scientific Information Research Group, providing the latest market intelligence
Our Integration with KnowledgePoint360
Access to market leading communications, education, meetings and e-solution platforms facilitates meaningful implementation of our strategic recommendations
